Question 1

Does Carlyle Group own SYRE stock?

Accepted Answer

No. Carlyle Group exited its SYRE (Spyre Therapeutics) position in Q2 2026. Its Q1 2026 13F listed 9,620 shares worth $485,233.

Question 2

How many shares of SYRE does Carlyle Group own?

Accepted Answer

None since Q2 2026, when Carlyle Group exited the position. Its Q1 2026 13F listed 9,620 shares worth $485,233.

Question 3

What is Carlyle Group's SYRE position worth?

Accepted Answer

Carlyle Group's SYRE position was worth $485,233 in its Q1 2026 13F, before the exit in Q2 2026.

Question 4

Is Carlyle Group buying or selling SYRE?

Accepted Answer

In Q2 2026, Carlyle Group exited its entire SYRE position.

Question 5

When did Carlyle Group first buy SYRE?

Accepted Answer

Carlyle Group first reported SYRE in its Q4 2023 13F and listed it in 7 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Exited	0	-100.0%	$0	0.0%	$88.78	0
2026-Q1	Unchanged	9,620	0.0%	$485,233	0.0%	$50.44	0
2025-Q4	New	9,620	—	$315,055	0.0%	$32.76	36
2025-Q1	Exited	0	-100.0%	$0	0.0%	$16.14	0
2024-Q4	Unchanged	9,620	0.0%	$223,761	0.0%	$23.28	0
2024-Q3	Unchanged	9,620	0.0%	$282,443	0.0%	$29.41	0